).
BRIEF COMMUNICATION
cerning the complex issue of consent to biobanking, a 12-page self-administered questionnaire that included a copy of the biobank consent form was designed and approved by the French National Committee on Personal Data and Privacy (CNIL). In February 2009, it was mailed to all 745 eligible adult patients who were diagnosed or treated for colorectal cancer, breast cancer, or a hematological malignancy between January 2007 and August 2008 and had tumor or blood samples that were cryopreserved at the biobank, whether or not they had given consent for the use of their samples for research purposes. Patients were ineligible if they had died (N = 26), had severe mental disorders (N= 4), were treated at other hospitals (N = 4), or had moved without leaving a forwarding address (N =26).
Of those questioned, 574 (77.0%) of the 745 patients responded (Supplementary Figure 1 , available online). Analysis of the returned questionnaires using two-sided (Student, x 2 ) statistical tests confirmed that respondents and nonrespondents did not differ significantly in terms of gender, age, or type of cancer (data not shown). At the time of the survey, 268 (46.7%) of the 574 patients reported having received the consent form and 213 (37.1%) of the 574 said that they had given their consent; 2 (0.3%) of the 574 said that they had refused consent; most of the others could not remember having received the biobank consent form (Supplementary Figure 1 , available online).
There were no statistically significant differences in age, gender, cancer type, education, employment, family status between patients whose consent had been registered (N = 267, 46.5%) and the others, although the time elapsed from cancer diagnosis to administration of the questionnaire was 6 weeks longer on average for the patients whose consent had been registered (Table  1) . However, we found that patients' declarations about their consent frequently disagreed with the recorded facts (Table 1 ; Kappa concordance index = .23). Of the 213 patients who remembered giving consent, only 131 (61.5%) actually had given consent and 82 (38.5%) had not. Of the 143 patients who declared that they never received the form (N = 131), had not There are still heated debates about which ways are best to obtain patients' consent for the use of their tumor cells and tissues in biobanking efforts and research. Opt-in procedures can provide patients evidence of good governance and respect for their autonomy (1) and can strengthen the social links with their caregivers (2). They also provide written proof that patients were duly informed, which is required for online tumor bank catalogs and exchanges of annotated samples for large-scale multicenter research projects (3). Although many articles concerning the ethics of informed consent have been published (4, 5) , few studies have focused on the patients' perception of the information and consent process (6) (7) (8) (9) , and none of these studies have addressed the quality of routine informed consent procedures. The aim of this study was to assess patients' opinions and understanding about the biobanking informed consent process in the framework of a routine "opt-in" scenario.
In many hospitals, the usual policy is that tumor cells and tissues are preserved shortly after surgery, whether or not the patient has signed a consent document, to ensure that biobank samples will be in perfect condition for any future biological analyses. Patients can give their consent for research use of specimens either at their initial visit or during follow-up visits. At our institution, since April 2002, it has been necessary to obtain the patients' formal signed consent (Supplementary Information, available online), which is registered in the electronic health records, to use biological samples stored at the biobank of the Institut Paoli-Calmettes, a regional cancer research center in southeastern France. Following a preliminary study of 30-to 50-minute interviews of 19 cancer patients about their views con-
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completed it (N = 10), or had refused consent (N = 2), 45 (31.5%) had actually completed and signed the form and 98 (68.5%) had not. Accurate recall of consent (356 of 574, 62.0%) was not associated with time elapsed since diagnosis (P = .323) or whether additional information had been provided by a health-care professional (P = .889); it was statistically significantly more accurate among patients who said they had received the form during follow-up (21 of 24, 87.5%) or treatment (53 of 74, 71.6%), rather than at their first admission (74 of 135, 54.8%) or among those who did not remember when they had received it (16 of 30, 53.3%; P = .004). Less than half of the patients who remembered giving consent (88 of 213, 41.3%) understood that consent also meant giving access to their medical data; this figure was similar
CONTEXT AND CAVEATS

Prior knowledge
There have been few studies regarding patients' attitudes and understanding of the informed consent process for biobanked materials.
Study design
Questionnaires were mailed to 745 cancer patients at a French cancer center with an opt-in system to ask whether they had given their consent for the use of biobanked specimens and to assess their attitudes towards biobanking and their understanding of the implications of consent.
Contribution
Many patients did not remember having giving consent, or believed to have given consent when they had not. Although most patients thought that consent for use of biobanked specimens should be necessary, fewer than half understood that consent gave researchers access to their medical data.
Implications
Better procedures are needed to solicit patient consent for the use of biobanked specimens.
Limitations
The study was done conducted at a single hospital, which may not be representative of every institution.
From the Editors Table 1 . * P values (two-sided) were calculated using the Student t test for continuous variables (age, number of children, time elapsed since cancer diagnosis) and the x 2 test for categorical variables (gender, cancer type, living with a partner, education, current employment, declared consent) using SPSS (SPSS Inc., Chicago, Illinois) 17.0. † This category includes 131 patients who reported never having received the consent form, 10 patients who claimed to have received it but not to have completed it, and only two patients who claimed to have completed the form and refused to give consent.
between patients who accurately recalled the consent process and the others (55 of 129: 42.6% vs 33 of 82: 40.2%; P = .731) and between patients who had received additional information from a health-care professional and those who had not (26 of 73: 35.6% vs 59 of 132: 44.7%; P = .206).
When questioned about their attitudes concerning informed consent, the majority of the patients (349 of 574, 60.8%) felt that biobank research should require patients' signed consent; however, even more thought that consent should be required for other kinds of research (two-sided McNemar test: P < .001; Table 2 ). This opinion was not associated with registered consent (P = .814) or accurate recall of consent (P = .330). Only 37 (6.4%) of the 574 patients thought that they would be the main beneficiaries of research (Table 2 ).
Most respondents expressed the opinion that biobanking of specimens should be subject to the patients' signed consent, consistent with previous findings (10). This figure might have been higher if more patients had realized that consent includes giving access to patients' clinical data. Future research on biological samples is likely to include genetic testing and identification. Although the Genetic Information Nondiscrimination Act promises to make genetic discrimination illegal (11), patients' wish to make signed consent mandatory will probably increase.
However, our study also brought to light two of the main limitations of the "opt-in" procedure. First, although few patients in our study group expressly refused consent, the real biobank consent rate was only 46.5%. Higher rates have been observed among selected patients, who had agreed over the telephone before a consent form was sent to them [66%, (12) ] or who were previously included in a clinical trial [89.4%, (13) ]. Low response rates are likely to introduce a selection bias into biobank studies (14, 15) . Second, although most patients understood that they were not the main beneficiaries of biobank research, the quality of the informed consent process was found to be less than satisfactory because the patients' recall was often faulty and they were unaware that giving their consent also meant giving access to their personal clinical data. In previous studies, the general population's understanding of biobanking research procedures was also found to be unsatisfactory (16) and patients' comprehension and recall of their signed consent could be insufficient (17, 18) . Although patients stated retrospectively that they preferred being given information before surgery, at admission, or during the hospital stay for cancer surgery (8), these may not be the most appropriate times. Discovering what biobanking means, that is, the intertwining of routine medical care with scientific research, is a process that gradually develops after diagnosis. The "end of treatment" period may therefore be the most appropriate time to solicit consent (19, 20) .
The main limitations of this study were first, that it was conducted at a single hospital because (a pioneer in introducing an opt-in procedure) and second, that despite a satisfactory response rate and no evidence for selection bias, respondents may not have been representative of all cancer patients. Despite these limitations, this study shows the need to improve biobank consent procedures. Although "opt-in" consent is perceived in a positive light by most patients, it will potentially introduce selection bias without necessarily improving the consent process if participation is not higher. Improving the quality of the information that is provided to patients will enable them to play an active part in the decision-making process and ensure that those who agree to allow their tissues and data to be used for research purposes are satisfied with the procedure and have really given their informed consent.
